课题基金 / 基金详情

项目摘要

项目成果

Edward Lakatta的其他基金

相似基金

相关文献

中文摘要
翻译
一些需要microrna,特别是miR-200家族和miR-34a专业知识的项目已经启动。研究表明,miR-200家族成员(共转录的miR-200c, -141;共转录的miR-200b, -200a, -429)和miR-34a在氧化应激反应中增加,这表明这些mirna可能在与活性氧(ROS)产生增强相关的条件下发挥功能作用,如衰老和糖尿病。一些miR-200家族成员在人类皮肤成纤维细胞和肝脏以及非人灵长类动物骨骼肌中表现出与年龄相关的增加。此外,miR-200c在老年和糖尿病啮齿动物的心肌、糖尿病啮齿动物的股动脉以及2型糖尿病和糖尿病足溃疡患者的皮肤细胞中升高。
英文摘要
Some projects that require expertise in microRNAs and, specifically, in miR-200 family and miR-34a, has been initiated. It has been shown that miR-200 family members (co-transcribed miR-200c, -141; co-transcribed miR-200b, -200a, -429) and miR-34a increase in response to oxidative stress suggesting that these miRNAs may play a functional role in conditions associated with enhanced production of reactive oxygen species (ROS) such as aging and diabetes. Some miR-200 family members exhibit an age-associated increase in human skin fibroblasts and liver, and in non-human primates skeletal muscle. Further, miR-200c increases within the myocardium of old and diabetic rodents, in femoral arteries of diabetic rodents and in skin cells of patients with type 2 diabetes and diabetic foot ulcers. He directs the conception and implementation of the following ongoing projects: Establish the role of miR-200 family members in myocardial function and its potential link to systolic and diastolic dysfunction in aging and diabetes; Establish the role of miR-200 family members and miR-34a in vascular dysfunction in aging and diabetes; Establish the expression level of circulating miR-200 family members in human aging, diabetes, obesity; Establish the role of miR-200 family members in skeletal muscle function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PUFA Dietary Intervention for Heart Rate
  • 批准号:
    8335786
  • 项目类别:
  • 资助金额:
    $25.83万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Decreased pacemaker activity in aged sinoatrial node
  • 批准号:
    8335801
  • 项目类别:
  • 资助金额:
    $11.03万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
  • 批准号:
    8552494
  • 项目类别:
  • 资助金额:
    $12.3万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
  • 批准号:
    9147229
  • 项目类别:
  • 资助金额:
    $15.43万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
海外基金